EFFICACY OF SINGLE DOSE INSTILLATION OF MITOMYCINC FOLLOWING TRANSURETHRAL RESECTION OF NON-MUSCLE INVASIVE BLADDER CANCER

ABSTRACT
Introduction: Bladder cancer is the fourth most commonly diagnosed cancer in men and eighth in women in the United
States (U.S). There are many predisposing factors of bladder cancer such as tobacco smoking. Chemicals, dye, rubber,
petroleum, leather and artificial sweeteners. Treatment includes Transurethral Resection of Bladder Tumor (TURBT),
Intravesical chemotherapy, Intravesical immunotherapy, radical cystectomy, systemic chemotherapy and radiotherapy.
There are different chemotherapeutic agents such as Mitomycin C, Thiotepa and Adriamycin for Intravesical use.
Objectives: To determine the efficacy of single dose instillation of Mitomycin C following transurethral resection of
non-muscle invasive bladder cancer.
Methods: It was a descriptive case series study, conducted at the Institute of Kidney Disease, Peshawar on the patients
admitted with bladder cancer and underwent TURBT. The duration of the study was one year in which a total of
128 patients were enrolled. After TURBT patientsreceived single dose of Intravesical Mitomycin within 24 hours. All the
patients were called back after 3 months for the check cystoscopy and the findings of the cystoscopy were recorded
so as to detect recurrence of bladder tumor.
Results: In this study 128 patients with transurethral resection of non-muscle invasive bladder cancer were observed,
with male to female ratio was 5:1. The age ranged from 18 to 75 years. The Bladder growth recurrence was found in
20 patients (15.62%) while 108 (84.38%) patients were free of recurrence.
Conclusion: Our study concludedthat the immediate post TURBT single doseof Intravesical Mitomycin is effective in
preventing the recurrence of Non Muscle Invasive Bladder Tumor.
Key Words: Efficacy of Mitomycin C, TURBT, Non Muscle Invasive Bladder Cancer